Theravance Biopharma (TBPH) Profit After Tax (QoQ) (2013 - 2026)

Theravance Biopharma (TBPH) Profit After Tax (QoQ) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Theravance Biopharma 864.82 Mn 470.15 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -108.08%
Dec 31, 2025 1,588.08%
Sep 30, 2025 -93.41%
Jun 30, 2025 503.82%
Mar 31, 2025 12.55%
Dec 31, 2024 -22.28%
Sep 30, 2024 23.18%
Jun 30, 2024 -41.71%
Mar 31, 2024 -37.06%
Dec 31, 2023 4.92%
Sep 30, 2023 42.79%
Jun 30, 2023 29.17%
Mar 31, 2023 -54.94%
Dec 31, 2022 -101.56%
Sep 30, 2022 3,549.87%
Jun 30, 2022 36.03%
Mar 31, 2022 28.15%
Dec 31, 2021 -63.74%
Sep 30, 2021 32.62%
Jun 30, 2021 34.23%